KB105 ( DrugBank: - )

---

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
160	先天性魚鱗癬	2

160. 先天性魚鱗癬

---

臨床試験数 : 42 /  薬物数 : 71 - (DrugBank : 21) / 標的遺伝子数 : 18 - 標的パスウェイ数 : 112

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05735158 (ClinicalTrials.gov)	March 2023	9/2/2023	Topical KB105 for the Treatment of TGM1-deficient Autosomal Recessive Congenital Ichthyosis (ARCI)	A Phase 2, Randomized, Placebo-controlled Study of Topical KB105, a Replication-defective, Non-integrating HSV-1 Vector Expressing Human Transglutaminase 1 (TGM1) for the Treatment of TGM1-deficient Autosomal Recessive Congenital Ichthyosis (ARCI)	Autosomal Recessive Ichthyosis	Biological: KB105;Other: Placebo	Krystal Biotech, Inc.	NULL	Not yet recruiting	6 Months	N/A	All	15	Phase 2	United States
2	NCT04047732 (ClinicalTrials.gov)	August 27, 2019	29/7/2019	Topical KB105 Gene Therapy for the Treatment of TGM1-deficient Autosomal Recessive Congenital Ichthyosis (ARCI)	A Phase I/II Clinical Trial of Topical KB105, a Replication-incompetent, Non-integrating HSV-1 Vector Expressing Human Transglutaminase 1 (TGM1) for the Treatment of TGM1-deficient Autosomal Recessive Congenital Ichthyosis (ARCI)	TGM-1 Related Autosomal Recessive Congenital Ichthyosis	Biological: KB105	Krystal Biotech, Inc.	NULL	Active, not recruiting	18 Years	N/A	All	6	Phase 1/Phase 2	United States